A clinical trial led by University College London (UCL) and UCL Hospitals (UCLH) reported follow-up results from NEOPRISM-CRC, testing a short course of immunotherapy prior to surgery for a subset of bowel cancer patients. The update described zero relapses in the trial results presented, drawing attention to how preoperative immunotherapy may reshape surgical sequencing.